REGULATORY

Japan's Global Health Confab to Prepare New Grand Design for Regulatory Harmonization in Asia

December 26, 2019

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

The Executive Committee on Global Health and Human Security plans to draft a new grand design to further promote regulatory harmonization in the fields of pharmaceuticals and medical devices in Asia after the middle of February next year, focusing on…

To read the full story

Japan Govt Maps Out Action Strategy for Regulatory Harmonization in Asia
July 15, 2020
Global Health Confab Issues Proposals for Regulatory Harmonization in Asia
March 31, 2020

REGULATORY

10 Firms Win Approval for Bilanoa Generics, 2 Contenders for Fycompa
February 17, 2026
MHLW to Brand OTC-Like Drug Cost Rule as “Partially Non-Insured Care”
February 17, 2026
Taiyo Pharma’s Propranolol Designated as Drug for Specific Use
February 17, 2026
Japan Grants Orphan Tag to Bayer, Incyte Drugs, and 12 Others
February 17, 2026
Japan to Delist 387 Drugs from NHI Price List, Including Renivace
February 16, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Is Calling for an Abolition the Right Play? Rethinking Japan’s FY2027 Off-Year Drug Price Revision

By Ken Yoshino

Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…

COLUMN

AI in Healthcare Hiring: Leveling the Playing Field & Unlocking Human Potential

By Philip Carrigan

The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…